Noveris Health Sciences is trading at CA$0.08, down -5.88%, primarily amid broader biotech weakness.
- No new company-specific announcement was identified for September 16, 2026; the latest located filing covered annual-meeting results published September 9.
- The sector ETF fell 2.11% during regular trading.
- Broader markets were mixed ahead of the Federal Reserve decision, making macro sentiment an additional, less direct influence.